Enrollment completed in Phase III Copaxone MS trial
Posted: Thu Jun 02, 2011 7:15 am
Teva Pharmaceutical Industries Ltd. today announced completion of patient enrollment for the GALA (Glatiramer Acetate Low-frequency Administration) trial. This international Phase III trial in patients with relapsing-remitting multiple sclerosis (RRMS), is designed to examine the efficacy, safe... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1767